Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies.

Marso SP, Lindsey JB, Stolker JM, House JA, Martinez Ravn G, Kennedy KF, Jensen TM, Buse JB.

Diab Vasc Dis Res. 2011 Jul;8(3):237-40. doi: 10.1177/1479164111408937. Epub 2011 Jun 8.

PMID:
21653676
2.

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.

Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ.

Lancet Diabetes Endocrinol. 2015 Sep;3(9):697-703. doi: 10.1016/S2213-8587(15)00233-8. Epub 2015 Aug 11. Erratum in: Lancet Diabetes Endocrinol. 2015 Oct;3(10):e8.

PMID:
26276240
3.

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E.

Diabetes Obes Metab. 2014 Jan;16(1):38-47. doi: 10.1111/dom.12175. Epub 2013 Jul 28.

PMID:
23829656
4.

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE.

Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.

PMID:
22055210
5.
6.

Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.

Zinman B, Schmidt WE, Moses A, Lund N, Gough S.

Diabetes Obes Metab. 2012 Jan;14(1):77-82. doi: 10.1111/j.1463-1326.2011.01493.x. Epub 2011 Oct 30.

PMID:
21883806
7.

The design of the liraglutide clinical trial programme.

Nauck MA.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:4-12. doi: 10.1111/j.1463-1326.2012.01573.x. Review.

PMID:
22405264
8.

The efficacy and safety of liraglutide.

Jeong KH, Yoo BK.

Int J Clin Pharm. 2011 Oct;33(5):740-9. doi: 10.1007/s11096-011-9552-8. Epub 2011 Sep 28. Review.

PMID:
21952951
9.

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, Pocock S, Steinberg WM, Bergenstal RM, Mann JF, Ravn LS, Frandsen KB, Moses AC, Buse JB.

Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2.

10.

Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.

Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M.

J Med Econ. 2012;15 Suppl 2:1-5. doi: 10.3111/13696998.2012.703633. Epub 2012 Aug 1.

PMID:
22853443
11.

Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Campbell RK.

Ann Pharmacother. 2009 Sep;43(9):1433-44. doi: 10.1345/aph.1M134. Epub 2009 Jul 28. Review.

PMID:
19638470
12.

Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.

Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I, Marchionni N, Mannucci E.

Exp Diabetes Res. 2011;2011:215764. doi: 10.1155/2011/215764. Epub 2011 Apr 26.

13.

Glycaemic control with liraglutide: the phase 3 trial programme.

Raskin P, Mora PF.

Int J Clin Pract Suppl. 2010 Oct;(167):21-7. doi: 10.1111/j.1742-1241.2010.02496.x. Review.

PMID:
20887301
14.

Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.

Ware JH, Vetrovec GW, Miller AB, Van Tosh A, Gaffney M, Yunis C, Arteaga C, Borer JS.

Am J Ther. 2013 May-Jun;20(3):235-46. doi: 10.1097/MJT.0b013e31828d455b.

PMID:
23615317
15.

Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.

Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, Ni Y, Liu D, Zhu Z.

Diabetes Obes Metab. 2013 Aug;15(8):737-49. doi: 10.1111/dom.12085. Epub 2013 Mar 20.

PMID:
23433305
16.

Early clinical studies with liraglutide.

Schmidt WE.

Int J Clin Pract Suppl. 2010 Oct;(167):12-20. doi: 10.1111/j.1742-1241.2010.02500.x. Review.

PMID:
20887300
17.

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.

Hoogwerf BJ, Lincoff AM, Rodriguez A, Chen L, Qu Y.

Cardiovasc Diabetol. 2016 May 17;15:78. doi: 10.1186/s12933-016-0393-6.

18.

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.

Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE.

Cardiovasc Diabetol. 2015 May 21;14:57. doi: 10.1186/s12933-015-0215-2.

19.

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.

Hermansen K, Bækdal TA, Düring M, Pietraszek A, Mortensen LS, Jørgensen H, Flint A.

Diabetes Obes Metab. 2013 Nov;15(11):1040-8. doi: 10.1111/dom.12133. Epub 2013 Jun 11.

20.

Is liraglutide a useful addition to diabetes therapy?

Mikhail NE.

Endocr Pract. 2010 Nov-Dec;16(6):1028-37. doi: 10.4158/EP10076.RA. Review.

PMID:
20439238

Supplemental Content

Support Center